Abstract 1093: Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort

Abstract Purpose: We report a blinded validation study of a ten-protein marker blood test for assessing risk of developing or harboring nine common cancers in a prospective lung cancer screening cohort. Patients and Methods: The foundation of the multi-cancer risk stratification test (MCaST), test is a 4-marker protein panel consisting of ProSFTPB, CEA, CA125, and CYFRA-21 which has been extensively validated for risk of lung cancer and which has been expanded to include six additional markers to encompass, in addition to lung cancer, prostate, colorectal, breast, ovarian, pancreatic, liver, esophageal, and stomach cancers. Blinded validation samples consisted of 1,235 plasmas collected prior to diagnosis from 171 cancer cases and 526 randomly selected non-case controls. Fixed individualized combination rules as well as cancer-specific risk thresholds predefined based on established clinical guidelines were applied. Results: At the subject level, the MCaST tested positive for imminent risk of lung cancer in 65 of 73 lung cancer cases, including 45 of 51 early-stage cases, with a median time of 12.7 months (interquartile range [IQR]: 1.7 - 27.8 months) between the first positive MCaST and diagnosis of lung cancer. The positive rate of MCaST for other cancers was 88.9% for prostate, 63.6% for invasive breast, 85.7% for CRC, 50% for ovarian, 50% for pancreatic, and 67% for esophagus plus stomach cancers with a median (IQR) time of 20.7 months (10.2 - 42.8 months) from the first positive MCaST to a clinical diagnosis across the cancer types. Overall accuracy for tissue-of-origin (TOO) signal was 94.6%, and as high as 98.1% for lung cancer. Conclusion: MCaST has utility for assessing cancer risk for common and lethal solid cancers in this smoker population. Citation Format: Ehsan Irajizad, Johannes Fahrmann, Hamid Rudsari, Jody V. Vykoukal, Iakovos Toumazis, Sara Khoramisarvestani, Sara Ansari, Jane Yang, Nicole M. Kettner, Jennifer B. Dennison, Edwin Justin Ostrin, Samir M. Hanash. Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1093.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-1093
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 1093: Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort

J. David Dennison, Iakovos Toumazis, Ehsan Irajizad, Nicole M. Kettner et al.
Cancer Research
Lung Cancer Research Studies
article

Abstract 1093: Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort

J. David Dennison, Iakovos Toumazis, Ehsan Irajizad, Nicole M. Kettner, Hamid Khoshfekr Rudsari, Edwin J. Ostrin, Johannes Francois Fahrmann, Sara Ansari, Jane Yang, J. Vykoukal, S. Khoramisarvestani, Samir M. Hanash
article en

Abstract

Abstract Purpose: We report a blinded validation study of a ten-protein marker blood test for assessing risk of developing or harboring nine common cancers in a prospective lung cancer screening cohort. Patients and Methods: The foundation of the multi-cancer risk stratification test (MCaST), test is a 4-marker protein panel consisting of ProSFTPB, CEA, CA125, and CYFRA-21 which has been extensively validated for risk of lung cancer and which has been expanded to include six additional markers to encompass, in addition to lung cancer, prostate, colorectal, breast, ovarian, pancreatic, liver, esophageal, and stomach cancers. Blinded validation samples consisted of 1,235 plasmas collected prior to diagnosis from 171 cancer cases and 526 randomly selected non-case controls. Fixed individualized combination rules as well as cancer-specific risk thresholds predefined based on established clinical guidelines were applied. Results: At the subject level, the MCaST tested positive for imminent risk of lung cancer in 65 of 73 lung cancer cases, including 45 of 51 early-stage cases, with a median time of 12.7 months (interquartile range [IQR]: 1.7 - 27.8 months) between the first positive MCaST and diagnosis of lung cancer. The positive rate of MCaST for other cancers was 88.9% for prostate, 63.6% for invasive breast, 85.7% for CRC, 50% for ovarian, 50% for pancreatic, and 67% for esophagus plus stomach cancers with a median (IQR) time of 20.7 months (10.2 - 42.8 months) from the first positive MCaST to a clinical diagnosis across the cancer types. Overall accuracy for tissue-of-origin (TOO) signal was 94.6%, and as high as 98.1% for lung cancer. Conclusion: MCaST has utility for assessing cancer risk for common and lethal solid cancers in this smoker population. Citation Format: Ehsan Irajizad, Johannes Fahrmann, Hamid Rudsari, Jody V. Vykoukal, Iakovos Toumazis, Sara Khoramisarvestani, Sara Ansari, Jane Yang, Nicole M. Kettner, Jennifer B. Dennison, Edwin Justin Ostrin, Samir M. Hanash. Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1093.

Cancer ResearchVol. 86(7_Supplement)
The University of Texas MD Anderson Cancer Center (US), Quest Diagnostics (United States) (US)
Good health and well-being
Openalex Percentile: Top 27%
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.